🇺🇸 FDA
Patent

US 11015211

Cardiac cell reprogramming with myocardin and ASCL1

granted A61KA61K38/1719A61K48/005

Quick answer

US patent 11015211 (Cardiac cell reprogramming with myocardin and ASCL1) held by Tenaya Therapeutics, Inc. expires Mon May 20 2041 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Tenaya Therapeutics, Inc.
Grant date
Tue May 25 2021 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon May 20 2041 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
16
CPC classes
A61K, A61K38/1719, A61K48/005